We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSynairgen Share News (SNG)

Share Price Information for Synairgen (SNG)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6.49
Bid: 6.00
Ask: 6.98
Change: -0.10 (-1.52%)
Spread: 0.98 (16.333%)
Open: 6.59
High: 0.00
Low: 0.00
Prev. Close: 6.59
SNG Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

TRADING UPDATES: Digital 9 raises cash; Bluejay and Rio start drilling

Mon, 24th May 2021 12:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

----------

Digital 9 Infrastructure PLC - digital infrastructure assets investor - Plans to raise GBP100 million through placing of shares at 105p each, 7.1% discount from Friday's closing price of 113p. Stock down 5.8% at 106.40p on Monday morning in London. "The net proceeds of the placing will be used to acquire further assets in line with the company's investment objective, identified in the company's pipeline of investment opportunities at IPO, as set out in the prospectus," Digital 9 says. "There are some GBP600 million of opportunities capable of completion in the next 12 months." Digital 9 listed at the end of March, raising GBP300.0 million.

----------

Bluejay Mining PLC - exploration and development company with projects in Greenland and Finland - Says drilling at Enonkoski nickel-copper-cobalt project in eastern Finland has begun. Rio Tinto Mining & Exploration Ltd, part of Rio Tinto PLC, is Bluejay's joint-venture partner at asset. "The 3,000 metre drilling programme targeting mineralisation in the Tevanjoki and Laukunsuo areas within Enonkoski will be followed by a period of analysis to be carried out by the JV partners," Bluejay says. In addition, company reports that pretax loss widens to GBP2.6 million in 2020 from GBP1.8 million in 2019. Like in 2019, Bluejay generates no revenue. Administrative expenses rise 11% to GBP2.5 million from GBP2.3 million. Posts only GBP49,360 in other gains, compared to GBP567,068 in 2019.

----------

Deltic Energy PLC - London-based natural resources investing company - Says Shell UK Ltd, Deltic's joint-venture partner at Licence P2252, calls on Fugro GB North Marine Ltd to carry out geophysical and geotechnical site survey works at Pensacola prospect in UK southern North Sea. Shell UK is part of Royal Dutch Shell PLC.

----------

US Solar Fund PLC - Americas-focused utility-scale solar power plant investor - Refinances existing debt facilities of 22-project Heelstone portfolio. Refinancing uses up USD92 million of USD132 million fundraise. Refinancing reduces effective interest rate to 3% per year, from 6.25%.

----------

Princess Private Equity Holding Ltd - Guernsey-based investment holding firm - Partially realises investment in International School Partnership. Says pension plan for municipal employees of the Province of Ontario agrees to buy 25% stake in ISP from Princess's invement manager Partners Group. Transaction values the international school network at EUR1.9 billion and Princess's stake at EUR150 million, compared to the stake's EUR139 million book value. ISP had been the largest Princess's largest holding at 14% of net assets. "As part of the transaction Princess will reduce its exposure to ISP but will retain an investment of approximately EUR20 million to continue to participate in the future growth of the business," it says.

----------

Frontier IP Group PLC - London-based intellectual property commercialisation firm - Portfolio firm Pulsiv raises GBP1.5 million. Pulsiv also names Darrel Kingham as chief executive. Kingham held a general manager role at Aixtron SE, a Herzogenrath, Germany-based maker of equipment for the semiconductor industry. Frontier IP CEO Neil Crabb says: "We are delighted to have attracted someone of Darrel's calibre as chief executive of Pulsiv. The company is now at an important stage, and we believe Darrel is the right person to take it forward through the next phase of its development."

----------

Fulcrum Utility Services Ltd - Sheffield-based multi-utility infrastructure and services provider - Awarded five-year deal with E (Gas & Electricity) Ltd worth GBP20 million. Fulcrum will provide smart meter exchange and management services, becoming E's meter operator and meter asset manager for a portfolio of 320,000 meter points in UK.

----------

Africa Opportunity Fund Ltd - closed-end investment company - Plans to return USD7.2 million to shareholders through mandatory redemption. Says USD7.2 million return is equivalent to 10.2 million shares.

----------

K3 Capital Group PLC - Bolton-based professional advisory services firm - Signs first debt facility as a PLC. Secures debt facilities worth GBP15 million, composed of a GBP10 million revolving credit facility with an accordion option of up to GBP5 million. "Alongside the company's existing cash reserves and strong ongoing cash generation, the facilities will be used to support the company's growth ambitions and its declared intention to acquire complementary professional services businesses," K3 says

----------

NetScientific PLC - Buckinghamshire-based life sciences and technology investment and commercialisation company - Reports on progress at 95%-owned ProAxsis Ltd. ProAxsis had "transformational" 2020, NetScientific says, as life sciences company made "significant corporate advancements". NetScientific adds: "The company expects to commercialise five novel/improved products over the coming year."

----------

Fragrant Prosperity Holdings Ltd - seeking acquisition in cannabis therapeutics - Signs letter of intent to acquire London-based cannabis wellness company CiiTECH Ltd for GBP17.5 million. Deal to be satisfied through issue of Fragrant shares at 5.25 pence each. Deal will be classed as reverse takeover, so Fragrant shares suspended from trading on the London Main Market.

----------

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Data finds SNG001 respiratory medication shows "potent antiviral activity" against Kent and South African Covid-19 variants. "As expected, these data confirm that SNG001 is a broad-spectrum antiviral product, now also demonstrating applicability against SARS-CoV-2 variants," Chief Executive Richard Marsden says.

----------

OnTheMarket PLC - property listing portal based in Aldershot, Hampshire - Signs commercial pact with Insurestreet Ltd, which trades as Canopy. Canopy provides tenant referencing services through its platform. "The partnership will enable OnTheMarket to provide its agent customers with free comprehensive tenant referencing, including employment and landlord references, for all tenancy applications," OnTheMarket says.

----------

Mountview Estates PLC - London-headquartered property manager - Reports on shareholder engagement following November general meeting which saw 33% of votes against the re-election of Chair Tony Powell and 31% against Mhairi Archibald's re-election as a non-executive director. Mountview says it identified "as far as possible" the shareholders who did not support the proposals. "Some shareholders did not wish to engage. The company remains committed to shareholder engagement and will continue to offer to have discussions with shareholders and will take into account their concerns and considerations in the future," Mountview says.

----------

Cloudcall Group PLC - Leicester, England-based provider of unified communications and contact centre software - Confirms trading for 2021 so far is in line with board expectations. "With both new business sales and upsells now running above pre-pandemic levels, revenue and platform usage is climbing steadily so that monthly recurring revenue, SMS and voice minutes are all at record highs and net renewal rates are back above 100%," says Chief Executive Simon Cleaver.

----------

Marlowe PLC - London-based business-critical services and software company - Acquires e-learning software platform Cylix Ltd for GBP1 million. Bath-based Cylix "broadens Marlowe's e-learning offering and will offer attractive synergies with Deltanet, our recently-acquired compliance & safety eLearning platform", company says.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
5 Sep 2022 10:42

Synairgen to collaborate with University of Southampton on observational study

(Sharecast News) - Drug discovery outfit Synairgen will collaborate with the University of Southampton on an observational study aimed at exploring and better understanding acute respiratory viral infections and recovery.

Read more
23 Jun 2022 16:02

UK shareholder meetings calendar - next 7 days

Friday 24 June 
AFC Energy PLCGM re fees for non-executive directors
Avast PLCAGM
Devolver Digital IncAGM
Entain PLCAGM
Gulf Keystone Petroleum LtdAGM
Hawkwing PLCAGM
Invesco Bond Income Plus LtdAGM
Life Science REITAGM
Northcoders Group PLCAGM
Princess Private Equity Holding LtdAGM
Monday 27 June 
Anglo-Eastern Plantations PLCAGM
Celadon Pharmaceuticals PLCAGM
Cizzle Biotechnology Holdings PLCAGM
Echo Energy PLCAGM
Medica Group PLCAGM
Pelatro PLCAGM
Surgical Innovations Group PLCAGM
Warpaint London PLCAGM
Tuesday 28 June 
4D Pharma PLCAGM
Acceler8 Ventures PLCAGM
Airtel Africa PLCAGM
Alina Holdings PLCAGM
Aquila Energy Efficiency Trust PLCAGM
Attraqt Group PLCAGM
Bay Capital PLCAGM
Capital & Counties Properties PLCAGM
CMO Group PLCAGM
Corre Energy BVAGM
Creo Medical Group PLCAGM
Futura Medical PLCAGM
Gama Aviation PLCAGM
ICG Enterprise Trust PLCAGM
ImmuPharma PLCAGM
IQE PLCAGM
Katoro Gold PLCAGM
Rockhopper Exploration PLCAGM
Sound Energy PLCAGM
TP Group PLCAGM
UK Oil & Gas PLCAGM
Volvere PLCAGM
Zegona Communications PLCAGM
Wednesday 29 June 
Africa Opportunity Fund LtdAGM
Argo Blockchain PLCAGM
Atome Energy PLCAGM
Brave Bison Group PLCAGM
Concurrent Technologies PLCAGM
Eden Research PLCAGM
Facilities by ADF PLCAGM
Gemfields Group LtdAGM
Golden Prospect Precious Metals LtdAGM
HeiQ PLCAGM
Helios Underwriting PLCAGM
Hurricane Energy PLCAGM
i(x) Net Zero PLCAGM
Lords Group Trading PLCAGM
MaxCyte IncAGM
Meggitt PLCAGM
Mobile Tornado Group PLCAGM
NB Distressed Debt Investment Fund LtdAGM
NetScientific PLCAGM
Provident Financial PLCAGM
RA International Group PLCAGM
Reabold Resources PLCAGM
Symphony Environmental Technologies PLCAGM
Team17 Group PLCAGM
ThinkSmart LtdGM re approval for capital return
Trinity Exploration & Production PLCAGM
URA Holdings PLCAGM
XP Factory PLCAGM
Zaim Credit Systems PLCAGM
Thursday 30 June 
3i Group PLCAGM
Ashtead Technology Holdings PLCAGM
Borders & Southern Petroleum PLCAGM
Caspian Sunrise PLCAGM
Cobra Resources PLCAGM
Crimson Tide PLCAGM
ECSC Group PLCAGM
Evraz PLCAGM
Gresham House Energy Storage Fund PLCAGM
GRIT Investment Trust PLCAGM
Gulf Marine Services PLCAGM
Hamak Gold LtdAGM
Hemogenyx Pharmaceuticals PLCAGM
Immotion Group PLCAGM
Inspiration Healthcare Group PLCAGM
Inspired PLCAGM
Jadestone Energy PLCAGM
Kanabo Group PLCAGM
Kropz PLCAGM
Likewise Group PLCAGM
Live Co Group PLCAGM
Location Sciences Group PLCAGM
LoopUp Group PLCAGM
M&C Saatchi PLCAGM
Microsaic Systems PLCAGM
Nostra Terra Oil & Gas CoAGM
Pathfinder Minerals PLCAGM
Playtech PLCAGM
Primorus Investments PLCAGM
Rockfire Resources PLCAGM
Roquefort Therapeutics PLCAGM
Sanne Group PLCAGM
Scottish Mortgage Investment Trust PLCAGM
Serica Energy PLCAGM
Supply@ME Capital PLCAGM
Surface Transforms PLCAGM
Synairgen PLCAGM
Tower Resources PLCAGM
Trainline PLCAGM
ValiRx PLCAGM
Victoria Oil & Gas PLCAGM
Watchstone Group PLCAGM
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more
25 May 2022 12:00

IN BRIEF: Synairgen shares fall as loss widens on higher costs

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Records a pretax loss of GBP57.9 million in 2021, widened from GBP17.7 million in 2020, as research and development costs jump to GBP52.9 million from GBP15.5 million. Further, administrative expenses more than double to GBP5.0 million from GBP2.2 million. Explains this with its phase 3 Sprinter trial that started patient recruitment in January 2021. The trial is for SNG001, an inhaled drug for the treatment of Covid-19. Says the remainder of the research and development expenditure was used for upscaling SNG001 manufacturing development activities and procuring long lead time components.

Read more
16 May 2022 15:23

Synairgen posts positive clinical trial data for SNG001

(Sharecast News) - Shares of Synairgen caught a bid following the release of clinical trial results which appeared to show that its SNG001 formulation against Covid-19 might lower the risk of severe disease or death in the most at risk patients.

Read more
16 May 2022 12:18

LONDON MARKET MIDDAY: FTSE 100 edges into green but grey clouds remain

(Alliance News) - The FTSE 100 index put a toe into positive territory by midday on Monday, reclaiming all the ground lost earlier in the morning, but investors continue to fret about poor economic data from China.

Read more
16 May 2022 12:18

IN BRIEF: Synairgen shares soar on positive analysis of SNG001

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Notes that it announced in February that its phase 3 Sprinter trial did not meet its primary endpoints of discharge from hospital and recovery. Says that the trial still showed an encouraging signal in the reduction in the relative risk of progression to severe disease or death within 35 days. Says that it performed a post hoc analysis on groups of patients recognised to be at greater risk of developing severe disease in hospital, to assess the strength of this signal. Says that the analyses showed stronger treatment effects with SNG001 in high-risk patient sub-groups, with the strongest effect observed in those who had clinical signs of compromised respiratory function. Says SNG001 significantly reduced the risk of progression to severe disease and death compared to a placebo by 70% in the per-protocol population.

Read more
17 Mar 2022 12:32

Synairgen falls as patient recruitment halted on Covid-19 trial

(Sharecast News) - Inhaled antiviral treatment developer Synairgen said on Thursday that the US National Institute of Allergy and Infectious Diseases (NIAID) has halted all patient recruitment in its phase 2 and 3 Covid-19 trial, which included the assessment of its 'SNG001' treatment.

Read more
17 Mar 2022 11:48

IN BRIEF: Synairgen falls as patient recruitment in US trial halted

Synairgen PLC - Southampton, England-based drug discovery and biotechnology company - Says the US National Institute of Allergy & Infectious Diseases has halted all patient recruitment in its phase 2/3 Covid-19 trial. The trial included the assessment of its inhaled SNG001 drug.

Read more
17 Mar 2022 11:21

AIM WINNERS & LOSERS: Synairgen sinks 18% after US Covid study halted

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
3 Mar 2022 20:34

TRADING UPDATES: Next Fifteen raises GBP50 million; N Brown sales up

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

Read more
3 Mar 2022 12:20

Synairgen asked to pause activities on Covid-19 treatment trial

(Sharecast News) - Synairgen announced on Thursday that it was pausing clinical trial activities on its 'SNG001' compound in the treatment of Covid-19, at the behest of American authorities.

Read more
3 Mar 2022 11:29

AIM WINNERS & LOSERS: dotDigital plunges after profit warning

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

Read more
21 Feb 2022 12:25

Synairgen falls as trial for Covid treatment fails to meet endpoints

(Alliance News) - Synairgen PLC shares hit a 12-month low on Monday after the biotechnology company said that the late-stage trial of its Covid-19 treatment SNG001 did not meet primary or key secondary efficacy endpoints.

Read more
21 Feb 2022 11:33

AIM WINNERS & LOSERS: Morses Club sinks on profit warning, CEO exit

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
21 Feb 2022 09:27

Synairgen shares plunge as Covid-19 treatment trial fails

(Sharecast News) - Synairgen announced on Monday that the international phase 3 trial of its SNG001 antiviral inhalation in patients hospitalised with Covid-19 did not meet its primary or key secondary endpoints.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.